Antiva Biosciences key facts
- Developer of small molecule antivirals designed to improve health outcomes for patients suffering from diseases caused by HPV and other viruses.
- Antiva Biosciences’s last known valuation is $123.0M.
- It has raised $144.8M across 4 recorded rounds; the latest was Early Stage VC ($38.5M) in Apr 2023.
- Notable investors include Mana Ventures, Gaingels, GV, University of California, Alexandria Venture Investments — 21 tracked in total.
- Antiva Biosciences has filed 6 Form Ds with the SEC since 2017, most recently Oct 2024 ($38.5M sold to 21 investors).
- Status: Privately Held (backing).
Who backs Antiva Biosciences
21+- ·The complete investor list: 21 names
- ·Watch Antiva Biosciences: the Monday email on marks, rounds and moves
Antiva Biosciences funding rounds
4 roundsAntiva Biosciences valuation
Antiva Biosciences's last known valuation is $123 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Antiva Biosciences raised?
Antiva Biosciences has raised $145 million across 4 recorded rounds since 2017. The largest was a $38.5 million early-stage round in Apr 2023.
Antiva Biosciences has filed 6 Form Ds with the SEC since 2017, most recently in Oct 2024 ($38.5 million sold to 21 investors).
Antiva Biosciences investors
21 investors are on record for Antiva Biosciences, including Mana Ventures, Gaingels, GV and University of California. By type, the record holds 7 venture capital firms. The early-stage round in Apr 2023 drew 21 investors.
About Antiva Biosciences
Developer of small molecule antivirals designed to improve health outcomes for patients suffering from diseases caused by HPV and other viruses. The company's antivirals are based on a medicinal chemistry platform that focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV, and animal retroviruses, enabling patients to recover from HPV-related diseases and other viruses.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2012
- Employees
- 26
- Website
- antivabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Antiva Biosciences’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.